Elucid Introduces Lesion Inspection Tool for Plaque-IQ Software Suite

April 20, 2026—Elucid announced the commercial availability of a new lesion inspection tool for coronary and carotid plaque analysis in its Plaque-IQ software suite.

Rapid Medical’s Tigertriever 25 Cleared by FDA to Treat LVO Stroke

April 16, 2026—Rapid Medical announced FDA clearance of the Tigertriever 25 thrombectomy device.

Three-Year Neuroguard IEP PERFORMANCE II Data Presented

March 13, 2026—Three-year outcomes from the PERFORMANCE II trial studying the Neuroguard Integrated Embolic Protection (IEP) 3-in-1 Carotid Stent System were presented by William A. Gray, MD, at the International Symposium on Endovascular Therapy (ISET).

CVRx Initiates BENEFIT-HF Trial of Barostim in Expanded Population

January 23, 2026—CVRx, Inc. a developer of neuromodulation solutions for patients with cardiovascular diseases, announced initiation of the BENEFIT-HF clinical trial.

C-GUARDIANS Data Published for InspireMD’s CGuard Prime Carotid Stent

January 16, 2026—InspireMD, Inc., developer of the CGuard Prime carotid stent system for the prevention of stroke, announced that results from the company’s C-GUARDIANS pivotal trial have been published by D.

SVS Issues Commentary on CREST-2

On behalf of the Society for Vascular Surgery (SVS), Ali AbuRahma, MD, Past President of SVS; Marc Schermerhorn, MD, Past Chair, SVS Document Oversight Committee; and Keith Calligaro, MD, President, SVS and SVS Executive Board, provided the following commentary on the CREST-2 results to Endovascular Today: The purpose of this commentary is to critically examine the CREST-2 results, discuss their implications for clinical decision-making for asymptomatic carotid artery disease, and guide clinicians toward optimizing patient outcomes.

CREST-2 Shows Reduced Stroke Risk With Carotid Artery Stenting Plus Intensive Medical Management; No Added Benefit Seen With CEA

November 21, 2025—In a pair of randomized, observer-blinded clinical trials designed to evaluate optimal management of asymptomatic carotid stenosis, Brott et al found that carotid artery stenting (CAS) added to intensive medical therapy significantly reduced stroke risk compared with medical therapy alone, while carotid endarterectomy (CEA) offered no significant additional benefit.

PERFORMANCE III 30-Day Outcomes Reported for Contego Neuroguard TCAR-IEP System

November 3, 2025—Contego Medical announced 30-day outcomes from the PERFORMANCE III study evaluating the Neuroguard IEP system for direct transcarotid artery revascularization (TCAR-IEP).

InspireMD Names Dr. Peter Soukas as Chief Medical Officer

November 3, 2025—InspireMD, Inc. announced the appointment of Peter A. Soukas, MD, as Chief Medical Officer. InspireMD is the developer of the CGuard Prime carotid stent system, which it launched in July 2025.

Elucid Launches PlaqueIQ Image Analysis Software for Carotid Arteries

October 29, 2025—Elucid announced the launch of its PlaqueIQ image analysis software for the quantification and classification of plaque morphology in the carotid arteries.